How to Cite:
Iqbal, F. (2023). Enhancing the effectiveness of Chimeric Antigen Receptor (CAR) T cells against tumors through CRISPR/Cas9-mediated PD-1 disruption. *International Journal of Health Sciences*, *7*(S1), 1836–1850. https://doi.org/10.53730/ijhs.v7nS1.14397

Enhancing the effectiveness of Chimeric Antigen Receptor (CAR) T cells against tumors through CRISPR/Cas9-mediated PD-1 disruption

Faisal Iqbal
Department of Biological Sciences, International Islamic University, Islamabad, Pakistan
Corresponding author email: faisalsaleh59@ymail.com / faisal.phdbt69@iiu.edu.pk

***Abstract*---**CAR T cell therapy is a cutting-edge method of treating cancer that entails altering a patient's own T cells to improve their capacity to combat cancer cells. This is accomplished by giving the T cells chimeric antigen receptors (CARs), which give them ability to recognize and precisely target cancer cells. T cells from the patient are first removed, and then their genes are modified to include CARs. The modified T cells are then reintroduced to the patient's body where they can more successfully target and eliminate cancer cells. CAR T cell immunotherapies and checkpoint inhibitors, notably PD-1 antagonists, have emerged as promising cancer therapeutic modalities. In this study, a novel method for producing PD-1-deficient anti-CD19 CAR T cells was devised, which combines lentiviral transduction with Cas9 ribonucleoprotein (Cas9 RNP)-mediated gene editing. The modified CAR T cells showed enhanced clearance of PDL1+ tumor xenograft in live animal models and higher efficacy in killing tumor cells in laboratory trials by interrupting the Pdcd1 (PD-1) gene. The combined effects of PD-1 disruption and CAR T cell therapy have the potential to significantly improve cancer immunotherapy. The genetic engineering is facilitated through a lentiviral-based vector, which is derived from an engineered form, used to introduce the CAR into the T cells. The CAR acts as a biological "program" that enables the modified T cells to recognize and target a specific antigen present on the surface of tumor cells. To ensure safety, the CAR T cells are carefully designed to exclusively target an antigen found on tumor cells and not on healthy cells. This targeted specificity helps minimize the risk of attacking normal tissues and maximizes the potential for effectively eliminating cancerous cells. Mice blood pressures were taken for 7 days (day and night) for behavior and any impact on CAR T cells purpose. The results of the study offer up new directions for investigating specialized and exact gene editing techniques to boost

the effectiveness of CAR T cell therapy and advance the area of cancer immunotherapy.

***Keywords*---**CAR T cells, Cas9 RNP, PD-1, PD-L1, CRISPR/Cas9.

1 Introduction

In the realm of cancer immunotherapy, CAR T cell therapy has become an innovative treatment. It entails modifying a patient's own immune T cells to more effectively identify and combat cancer cells. When used to treat certain cancers, notably hematological malignancies like leukemia and lymphoma, this therapy has demonstrated astoundingly effective results. The process of CAR T cell therapy begins with the collection of T cells from the patient's blood. These T cells are then genetically modified in the laboratory to express chimeric antigen receptors (CARs) on their surface. The CARs are designed to target specific antigens present on the surface of cancer cells. Once the CAR T cells are multiplied in the lab, they are infused back into the patient's body, where they can locate and destroy cancer cells more effectively. Specific types of B cell leukemia and lymphomas may be treated with chimeric antigen receptor (CAR) T cells. Effectively tackling various liquid and solid tumor types still presents difficulties, though. It is now possible to improve CAR T cell treatment by genetic modification or disruption thanks to the development of CRISPR/Cas9-based gene editing for primary human T cells. This study evaluated the possibility of enhancing anti-CD19 CAR T cells by blocking the PD-L1 receptor on tumor cells. Genetically altered human CAR T cells were created using a technique that combines lentiviral transmission with Cas9-based gene disruption. The study evaluated whether Cas9-mediated disruption of PD-1 in CAR T cells could improve their ability to fight tumors both in vitro and in real creatures using a xenograft tumor model. The success of CAR T cell therapy has been particularly significant in cases where traditional treatments like chemotherapy and radiation have failed or have not been effective enough. It has offered new hope to patients who had limited treatment options and potentially provides long-term remission for some patients.[1-6]

Despite its success, CAR T cell therapy is not without challenges. One of the significant challenges is the potential for severe side effects, known as cytokine release syndrome (CRS) and neurologic toxicities, which can be life-threatening in some cases. Researchers are continually working to improve the safety and efficacy of CAR T cell therapy, and there have been advancements in managing these side effects.[7-9]

The PD-1/PD-L1 axis intimately controls T cell activation and destiny. While PD-1 is momentarily increased on activated T cells, its persistent expression is linked to T cell weariness, which is characterized by decreased activity. This behavior is seen in advanced cancer tumors and T lymphocytes invading persistent viral infections. PD-1, PD-L1, and PD-L2 ligands are frequently associated with different prognosis in a variety of cancer types. The PD-1/PD-L1 axis plays a crucial role in anti-tumor immunity, since studies have shown that blocking antibodies against PD-1 or PD-L1 can trigger powerful anti-tumor immune

responses in patients with various malignancies. The purpose of the study was to determine if deleting Pdcd1 gene from CAR T cells could result in the development of T cells with improved tumor cell detection and elimination skills. Although prior research has suggested that inhibiting PD-1 can improve the efficacy of CAR T cells, it is unclear how much PD-1 affects these cells. As widespread PD-1 inhibition may have negative effects, directly targeting Pdcd1 within CAR T cells may offer a less dangerous method of overcoming tumor-related immune suppression. According to the research, blocking the TCR and removing Pdcd1 from CAR T cells may inhibit the activation of self-reactive T cells.[10-14]

This study sought to determine whether primary human CAR T cells natural Pdcd1 gene disruption could enhance these cells capacity to fight tumors. However, by utilizing Cas9 to destroy the Pdcd1 gene inside the CAR T cells, this inhibition may be overcome. Lentiviral transduction and CRISPR-based gene editing were very effective methods for introducing genetic alterations. Future improvements to cell therapy products could result from this finding, making them safer and more potent against tumors. As with any emerging field, ongoing research and clinical trials are crucial for the development of safe and effective gene therapy drugs and CAR T cell therapies. The hope is that these innovative approaches will continue to improve and become more accessible, providing new and improved treatment options for cancer patients in the future.[15-24]



Figure 1: CAR-T cell therapy

CAR-T cell therapy is a kind of treatment in which a patients T cells are genetically engineered in lab and bind with a specific proteins (antigens) on cancer cells and kill them. (1) A patients T cells are removed from their blood, (2) then reprogram the T cells with Chimeric Antigen Receptors (CAR) in the lab. (3)

The millions of CAR T cells are grown in the lab, (4) then CAR T cells are given to the patients with intravenous infusion. (5) The CAR T cells bind to antigen on the cancer cells and kill them.

2 Materials and Methods

2.1 In vivo research frame

Institutional animal care gave its approval to all experiments using animals, and all of them adhered to the standards and regulations the organization had established.

2.2 T cell extraction, growth and construction of lentiviral vector:

For this research human T cells were obtained from donors who gave their verbal assent and gave their consent voluntarily. Using the EasySep negative selection technique, CD4+ or CD8+ T lymphocytes were separated and cryopreserved in RPMI medium containing 20% human AB serum and 10% DMSO. After defrosting, the cells were placed in T cell medium (TCM), which was supplemented with IL-2 (18U/mL), to rest for the night before activation. The X-Vivo 15 (Lonza), 3% human AB serum (Valley Biomedical), 45 mM -mercaptoethanol, and 5 mM N-acetyl L-cysteine components of the TCM formulation. While the lentiviral vector production process was executed following a specific protocol. The anti-CD19 4-1BBζ CAR construct, initially provided by the University of Pennsylvania. To create the PD-L1 lentiviral vector, a codon-optimized human PD-L1 gene was synthesized by IDT and inserted into the BamHI site of the lentiviral vector pHR'SIN: CSW through In-Fusion cloning from Clontech.

2.3 Cell culture condition and characterization

The Iscove's Modified Dulbecco's Medium (IMDM) used in the study, which provides vital nutrients and growth elements for cell growth and maintenance, was supplemented with 5% fetal bovine serum (FBS). To ensure ideal cell health and reproducibility of results. A certain amount of CD19+ K562 cells were treated to lentiviral supernatant containing genetic material to introduce PD-L1 expression into the cells in order to create the CD19+ PD-L1+ cell line. The cells were able to acquire the PD-L1 gene and express the PD-L1 protein on their surface through a process known as transduction.

2.4 Method for intracellular detection and T cell degranulation assessment

The stains from Invitrogen were used in accordance with the directions provided to prepare the cell surface for staining. Unless otherwise stated, the staining procedure was performed in RPMI medium supplemented with 1% FBS at a temperature of 4°C after quenching and washing. For each objective, particular clones of antibodies from various suppliers were employed. These included BD's RPA-T8 for anti-CD8, H4A3 for anti-CD107a, EH12.2H7 for anti-PD-1, BD's MIH1 for anti-PD-L1, BD's FN50 for anti-CD69 and BD's HIB19 for anti-CD19. FlowJo was helpful for analysis due to data collection using an LSR II from BD. While The CD8+ anti-CD19 chimeric antigen receptor (CAR) T cells used in this test were

given the opportunity to rest in order to assure best performance. The target cells, specifically CD19+ K562 cells or CD19+ PD-L1+ K562 cells, were then co-cultured with these CAR T cells in a ratio of 1:2. Anti-CD107a, a marker frequently used to evaluate degranulation, a crucial functional response of cytotoxic T cells, was added to T cell media for the co-culture. The cells were stained with a living or dead stain and an anti-CD8 antibody after 4 hours of co-culture in order to distinguish between living and dead cells and to particularly detect the CAR T cells. The cells were then examined using flow cytometer. Expression of CD107a is a sign of degranulation, the release of cytotoxic granules by cytotoxic T cells that contain chemicals that can target and kill target cells.

2.5 Assay for in vitro cytotoxicity and T cells editing via Cas9 RNP

Target cells of two different types- CD19+ (Ag+) K562 cells and antigen-irrelevant (Ag) K562 cells- were used in this experiment. CellTrace Violet was used to label the CD19+ cells, while CellTrace Far Red was used to mark the Ag+ cells. In 96-well plates, $1x10^3$ total K562 cells were planted per well after the CD19+ and CD19+ PD-L1+ (Ag+) cells were mixed with the Ag cells in a 1:1 ratio. At different effector-to-target ratios, rested CD8+ anti-CD19 CAR T cells were infused into the target cells. The cells were extracted and stained with Live/Dead dye to discriminate between live and dead cells after 18 hours of co-culture. The cells were examined using flow cytometry to measure the precise lysis of the target cells by the CAR T cells. While The Cas9 RNP (Ribonucleoprotein) editing approach was used to modify primary human CD4+ or CD8+ T cells, and the standard protocol was modified. The T cells were defrosted and given 24 hours of rest in TCM (T Cell Medium) as the first step in the procedure. In a T cell medium with added IL-2, the T cells were then activated with anti-CD3 and anti-CD28 antibodies for the following 48 hours. The procedure of alteration was carried out using the electroporation method. In particular, the 4D-Nucleofecter and Amaxa P3 primary cell kit were used. It was done using recombinant Cas9 protein from S. pyogenes. These components made it easier for Cas9 to breach the nuclear membrane. In a solution of 18 mM HEPES at PH 7.5, 140 mM KCl, 10% glycerol, and 1 mM TCEP, the Cas9 protein was kept at -80°C, below the freezing point. Freshly made Cas9 ribonucleoproteins (RNPs) were used for each experiment. To do this, equal amounts of chemically synthesized tracrRNA and crRNA, both of which targeted a particular region of the Pdcd1 gene's exon 1, were mixed together. Afterward, the mixture was incubated at 37°C for 25 minutes, producing a duplex with a 40 μM concentration. In the duplex mixture, S. pyogenes Cas9-NLS was then gradually added at a concentration of 35 μM. Cas9 RNPs with a concentration of 18 μM were produced by re-incubating the mixed solution at 37°C for 12 minutes. The previously activated T cells were put through a technique known as nucleofection employing a mixture comprising 2 μl of the 18 μM Cas9 RNP. These nucleofected T cells were then seeded at a density of 1 million cells per milliliter in a medium called TCM. A 1:1 bead-to-cell ratio of Dynabeads human T activator anti-CD3/anti-CD28 was present in this medium. Lentiviral supernatant was added to the cell wells and left to incubate for 20–24 hours in order to introduce the required genetic alterations. After this incubation, the beads were taken out of the cell mixture three to four days later.

2.6 Analysis of Pdcd1 disruption and immunodeficient mouse model

A particular PCR (Polymerase Chain Reaction) method was used to increase the genomic regions encompassing the Cas9 target site within the PD-1 target region. The specific primers created for PCR that were used to conduct it. Both the modified and control samples genomic DNA, equal to 100 ng, was utilized in the PCR process. Kapa hot start high-fidelity polymerase was used according to the manufacturer's recommendations. While in this study, female NOD-scid-IL-2Rγ−/− (NSG) mice, aged between seven to nine weeks, were acquired from the USA and utilized as the immunodeficient mouse model. To induce tumor growth, the mice were subcutaneously injected with either 5×10^3 logarithmic growth phase CD19+ K562 cells or CD19+ PD-L1+ K562 cells. Once the tumors reached a volume of 100–450 mm^3, different types of CAR T cells were introduced into the mice through intravenous injection. The CAR T cells included 2×10^3 CAR+ CD4+ and 2×10^3 CAR+ CD8+ control CAR T cells, as well as PD-1 edited CAR T cells. Tumor growth was monitored over time using an electronic caliper to measure tumor size longitudinally. The experiment aimed to evaluate the effectiveness of PD-1 edited CAR T cells in comparison to control CAR T cells in targeting and shrinking the CD19+ and CD19+ PD-L1+ tumors in the immunodeficient mouse model. Monitoring tumor growth provided valuable insights into the potential therapeutic impact of the modified CAR T cells in cancer treatment.

3 Results

The study's goal was to determine whether the presence of PD-L1 on tumor cells may impair CAR T cells ability, created CD19+ PD-L1+ K562 cells by introducing human PD-L1 into CD19+ K562 myelogenous leukemia cells, resulting in tumor cell lines that expressed PD-L1. These K562 cells were selected because to their absence of MHC I expression and the fact that they do not cause CD8+ CAR T cells to undergo TCR-mediated signalling, thereby removing any potential complicating considerations. So used a second-generation anti-CD19 4-1BB CAR, recognized for its powerful anti-tumor properties. They used primary human CD8+ T cells, which were subsequently genetically transformed using a lentiviral vector harboring the anti-CD19 CAR after being stimulated with anti-CD3/anti-CD28 beads. To evaluate PD-L1's effect on CAR T cell performance, these modified CD8+ T cells were stimulated by either CD19+ or CD19+ PD-L1+ K562 cells. According to the results, targets that were CD19+ PD-L1+ showed 12% less degranulation and were 10–35% less likely to be destroyed by anti-CD19 CAR T cells during an overnight killing trial. These results strongly suggest that primary human CD8+ T cells carrying the anti-CD19 4-1BB CAR cannot effectively fight cancer cells when PD-L1 expression is present on tumor cells.

3.1 Tumor clearance

This study's major goal was to determine whether the presence of PD-L1 may affect how well CAR T cells functioned and how well tumors were cleared in an in vivo environment. So used the NOD-scid-IL-2RY/ (NSG) mice, an immunodeficient animal model, to accomplish this. By subcutaneously injecting either $5x10^3$ CD19+ K562 cells or CD19+ PD-L1+ K562 cells into these animals, tumors were created. The tumors on the mice were given time to expand to a size of roughly

100-220mm. Next, the intravenously transferred 2×10^3 CD4+ and 2×10^3 CD8+ anti-CD19 CAR T cells into the mice. The inclusion of both CD4+ and CD8+ CAR T cells mimicked current clinical protocols for CAR therapy. This experimental design allowed to observe and compare the clearance of tumors in the presence of PD-L1 (CD19+ PD-L1+ tumors) versus tumors without PD-L1 (CD19+ tumors). To understand the effect of PD-L1 on CAR T cell function and its potential impact on the efficacy of CAR T cell immunotherapy in vivo by assessing tumor clearance in response to the transplanted CAR T cells. The results of this study could have a big impact on how CAR T cell therapies are improved to be more successful against tumors that express PD-L1.



Figure 2: This work investigates how anti-CD19 CAR T cell function is influenced by the presence of PD-L1 in K562 myelogenous leukemia cells, both in controlled laboratory settings and in living organisms. In Panel (A), the information shows that CD8+ anti-CD19 CAR T cells exhibit less degranulation after being re-stimulated with CD19+ PD-L1+ K562 cells. This decrease in degranulation was noticed in numerous separate trials. The experiment is shown in Panel (B), where CD19+ PD-L1+ K562 cells show resistance to lysis by anti-CD19 CAR T cells in an in vitro killing assay. When compared to CD19+ K562 cells, there is less selective lysis, which demonstrates this. A comparison of CD19+ PD-L1+ and CD19+ cells for normalized killing is shown in Panel (C), along with details of the experimental setup. The results of subcutaneous xenograft tests are presented in Panel (D), which conclusively demonstrate that CD19+ PD-L1+ cells impair the ability of anti-CD19 CAR T cells to eradicate tumors. These panels show how, in both

controlled lab settings and real-world circumstances, PD-L1 expression in tumor cells can reduce the potency of anti-CD19 CAR T cells.

3.2 Gene editing based PD-1 deficient human CAR T cells

The objective of the study was to create a unique technique that combine Cas9 ribonucleoprotein (RNP) gene editing with lentiviral transduction of primary human T cells. It had been demonstrated in earlier research that Cas9 RNP electroporation was a useful technique for gene editing in primary human T cells. In this modified technique, T cells were first stimulated with anti-CD3 and anti-CD28 antibodies to confirm their readiness for CAR transduction and gene editing. The Cas9 enzyme was used to make it possible for the T cells to precisely and exclusively delete the PD-1 gene. Following gene editing, the T cells were transduced with the anti-CD19 CAR using a lentiviral vector, effectively engineering them to target CD19-expressing cancer cells. To support the expansion of the modified CAR T cells, they were cultured with anti-CD3/anti-CD28 beads, allowing for proliferation and amplification. This novel approach targeted to reduce PD-1 expression by combining Cas9 RNP gene editing with lentiviral transduction to improve the functioning of CAR T cells. The final objective was to enhance the anti-PD-L1+ cancer cell activity of CAR T cell immunotherapy, perhaps resulting in improved cancer treatment outcomes. The success of PD-1 removal and CAR transduction accomplished using lentiviral transduction was assessed using flow cytometry analysis performed 2-4 days after performing nucleofection on the cells. Sequencing was done on both the Cas9 control and PD-1 edited samples to confirm the molecular-level editing. These results confirmed that the PD-1 gene was successfully edited.

3.3 CAR T cells of PD-1 edited genes

In lab experiments, PD-1 edited anti-CD19 CAR T cells were used to examine how the absence of PD-1 affects CAR T cell functionality. Large cell populations, both edited and unedited cells, were used for these tests. The findings showed that editing of Pdcd1 (PD-1) was efficient in correcting the lack of degranulation seen in CD8+ CAR T cells after being stimulated by CD19+ PD-L1+ tumor cells, as opposed to the control cells that underwent Cas9 nucleofection without PD-1 disruption. Furthermore, the study evaluated the ability of PD-1 edited anti-CD19 CAR T cells to destroy both CD19+ and CD19+ PD-L1+ targets. The outcomes revealed that PD-1 edited CD8+ CAR T cells exhibited enhanced efficacy in eliminating PD-L1+ tumor cells compared to the control cells subjected to Cas9 nucleofection. In short, these findings suggest that disrupting Pdcd1 can effectively reverse functional impairments caused by PD-L1+ tumor cells in CD8+ anti-CD19 4-1BBζ CAR T cells, highlighting the potential of this approach to improve CAR T cell therapy against such tumors.

The study found that PD-1 modified CAR T cells significantly outperformed control anti-CD19 CAR T cells in tumor clearance, especially in mice with initial tumor diameters between 100 and 220 mm. Compared to animals treated with PD-1 modified CAR T cells, only one out of five mice treated with control anti-CD19 CAR T cells shown complete tumor eradication in 25 days after tumor implantation. The number of CAR T cells transplanted had an impact on how well

the treatment worked. Mice that received $2x10^3$ CD4+ CAR+ and $2x10^3$ CD8+ CAR+ cells of either control or PD-1 modified cells failed to show tumor eradication. Although this difference was not deemed statistically significant, the median survival of animals treated with PD-1 modified cells was 33 days as opposed to 20 days for those receiving control cells. In cases where animals had smaller initial tumors (50-80 mm) and were treated with a larger quantity of CAR T cells (4×10^3 CD4+ CAR+ and 4×10^3 CD8+ CAR+ cells), PD-1 edited CAR T cells demonstrated quicker tumor clearance compared to the control cells. It's worth noting that both un-edited and edited cells managed to clear CD19+ PD-L1+ tumors when the initial tumor burden was low and a high dose of T cells was administered. In conclusion, these findings indicate that specifically targeting the Pdcd1 gene using CRISPR technology can enhance the in vivo effectiveness of human CAR T cells against tumors.

This study shows that anti-CD19 4-1BBζ CAR T cells can't operate well when there is PD-L1 expression on tumors, both in a lab setting under strict control and in a subcutaneous tumor xenograft model. This problem was solved using a unique method that combines Cas9 RNP editing and lentiviral transduction to produce anti-CD19 CAR T cells deficient in functional Pdcd1. When CAR T cells were co-cultured with PD-L1+ tumors in vitro, this ground-breaking method successfully overcame many of the shortcomings that had been noticed, leading to the successful removal of PD-L1+ tumors in vivo. These results highlight the PD-1/PD-L1 axis's inhibitory function in limiting CAR T cells' antitumor capacities. Furthermore, they provide strong proof for the possibility of using Cas9-based gene editing to boost the efficiency of CAR T cell therapy, bringing up new opportunities for the advancement of cancer treatment.



Figure 3: To demonstrate that CRISPR based PD-1 editing rescues anti-CD19 CAR T cell function in vitro and enhances tumor clearance in vivo panel (A) shows a diagram in comparison to CAS9 control and ΔPD-1 degranulation. Panel (B) demonstrate that partially resistant to CD19+ PD-L1+ mediated suppression of cytolysis are PD-1 modified CAR T cells. It is displayed the % of lysis for control and PD-1 modified CD8+ anti-CD19 CAR T cells. Panel (C) Clear subcutaneous CD19+ PD-L1+ tumor xenograft and improved anti-tumor effectiveness are shown by PD-1 defective anti-CD19 CAR T cells. In panel (D) only one out of five mice treated with control anti-CD19 CAR T cells shown initial tumor (100-220mm) eradication in 25 days after tumor implantation. In cases where mice had smaller initial tumors (50-80 mm) and were treated with a larger quantity of CAR T cells demonstrated fast tumor clearance compared to the control cells.

3.4 Mice blood pressure

In the cardiac cycle, during one heartbeat of maximum pressure is systolic while minimum pressure of between two heartbeats is diastolic. Mice blood pressure were taken for consecutive seven days (day and night) to check behavior, on different blood pressure mice were behave differently, only two mice were used for this purpose. The blood pressure impact on the CAR T cells were noticed but more authentic research data is required.



Figure 4: Mice blood pressure

The panel (A-1 and B-1) describing the two different mice average systolic and diastolic data, while (A-2 and B-2) is presenting distribution data of systolic and diastolic. Heart log app from Apple store was used for graphical data.

4 Discussion

Several issues that are raised by the results of this study. According to earlier studies on TCR signalling, PD-1 activation can reduce Akt pathway signalling and have other outcomes. Uncertainty still exists regarding the precise mechanisms by which the combination of PD-1 and PD-L1 affects the activation of CAR T cells. Finding the precise threshold at which PD-1 interaction impairs CAR T cell signalling or function will open the door for the development of CARs with extra or alternative costimulatory domains that can combat PD-L1-mediated immune suppression. Finding this key threshold might make it easier to create and improve CARs that are more resistant to PD-L1's inhibitory effects. It will also be crucial to determine whether the deletion of Pdcd1 has different effects depending on the particular type of CAR being used. Different costimulatory domain-carrying CAR T cells display a range of phenotypes, activity levels, and PD-1 expression.

For CAR designs to attain the best anti-tumor activity, an understanding of these subtleties will be essential.

In order to control the immune response and keep the body's immune system in balance, PD-1/PD-L1 and CD8+ T cells work together. On the surface of T cells, particularly CD8+ T cells, is a receptor called PD-1 (Programmed Cell Death Protein 1). The ligand PD-L1 (Programmed Death-Ligand 1) is expressed on a variety of cells, including certain immune cells and cancer cells. When CD8+ T cells come into contact with malignant or contaminated cells, they get activated and launch an immune response to destroy the aberrant cells. To prevent overly inflammatory conditions and tissue damage, this reaction must be strictly managed.

There is widespread agreement that PD-1/PD-L1 and the depletion of CD8+ T cells are related. As a result, this study's main objective was to look at CD8+ T cells in a lab setting. However, this work included both CD4+ and CD8+ T cells for its in vivo investigations because the clinical trials now investigating CAR T cell therapies frequently include both CD4+ and CD8+ T cells. Surprisingly, it was shown that the ablation of Pdcd1 in CD4+ T cells stopped this process of fatigue and improved tumor clearance. Future studies should therefore focus further on investigating the effects of disrupting Pdcd1 in CD4+ and CD8+ CAR T cells, both separately and in combination. Gaining a deeper understanding of the possible advantages and drawbacks of Pdcd1 modification across various T cell subsets in the context of CAR T cell treatments depends on this thorough investigation.

Engineered human xenograft models provide a regulated setting for researching particular biological processes. Additional studies using T cells in models with different inhibitory receptors may be helpful in examining the effect of inhibitory receptor signalling on CAR T cell activity. A powerful and effective technique for research and breakthroughs in adoptive immunotherapy is the genetic alteration of primary human T cells. Modifying Pdcd1 in CAR T cells could improve their anti-tumor efficiency, especially for lymphoma patients, and possibly lower the number of cells needed for treatment. The possibility that Pdcd1-deficient CAR T cells can express auto-reactive T cell receptors (TCRs) and cause autoimmune adverse effects akin to those seen with systemic PD-1 antibody suppression must be taken into account. The insertion of guide RNAs that target the endogenous TCR and subsequent selective reduction of TCR+ cells could be an approach to reduce this danger. To reduce the danger of graft-versus-host illness, this strategy intends to produce highly effective, tumor-specific CAR T cells that do not recognize non-CAR antigens. It is crucial to thoroughly study off-target effects and genotoxicity related to the given guide RNAs before applying CRISPR/Cas9-based therapeutics in human patients. Utilizing powerful Cas9 RNP-based T cell editing could offer insights into the basic biology of human T cells and possibly uncover novel targets to improve the effectiveness of anti-tumor T cells. Last but not least, knock-in genetic alterations could be used to investigate gain-of-function mutations, providing chances to develop improved cellular therapeutics for a variety of illnesses. The ability to perform targeted genome engineering of human tumor-specific T cells and examine their functional effects both in laboratory settings (in vitro) and within living organisms (in vivo) is anticipated to significantly influence the development of the next generation of immunotherapies

for cancer. Accurately alter the genetic make-up of T cells to improve their anti-tumor capabilities by using cutting-edge genome editing tools like CRISPR/Cas9. Through focused engineering, CAR T cells can be produced that are more potent, more tumor-specific, and have less off-target effects. The effectiveness and safety of modified T cells can be evaluated in vivo studies using animal models, such as mice xenograft or patient-derived xenograft (PDX), in a setting that is more physiologically realistic. The mice's blood pressure during the experiment was also helpful for research data. Important information on the therapeutic potential and potential negative consequences of the modified T cells is obtained by observing their interactions with tumor cells and the host immune system in vivo. Overall, the use of targeted genome engineering along with functional evaluations in both in vitro and in vivo environments enables the development of more potent and secure cancer immunotherapies. With the advent of a new era in cancer immunotherapy and improved therapeutic results for patients, this strategy holds out the possibility of personalized and precise treatments that can target tumors with previously unheard of accuracy.

5 Conclusion

The study demonstrated that CAR T cells capacity to kill tumor cells, both in controlled laboratory settings and within living individuals. Overall, this study highlight how precise genome editing could improve existing cell-based therapies and ultimately increase the effectiveness of CAR T cell immunotherapy. It clarifies the promising strategy of applying genetic alterations to increase the effectiveness of CAR T cells against malignant cells.

Declaration of interest: Author declare no competing interest.

References

1. Mandal, P. K., Ferreira, L. M., Collins, R., Meissner, T.B, Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B.S., Stortchevoi, A., Bryder, D., Musunuru, K., Brand, H., Tager, A.M., Allen, T.M., Talkowski, M.E., Rossi, D.J., and Cowan, C. (2014). A. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell, 15(5), 643-652.
2. Schumann, K., Lin, S., Boyer, E., Simeonov, D.R., Subramaniam, M., Gate, R.E., Haliburton, G.E., Ye, C.J., Bluestone, J.A., Doudna, J.A., and Marson, A. (2015). Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A, 112(33), 10437-42.
3. Méndez-Mancilla, A., Wessels, H.H., Legut, M., Kadina, A., Mabuchi, M., Walker, J., Robb, G.B., Holden, K., and Sanjana, N.E. (2022). Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells. Cell Chem Biol, 29(2), 321-327.
4. Rosenberg, S. A. and Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348, 62–68.
5. Bryan, L. J. and Gordon, L. I. (2015). Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies. Oncology, 29, 431–439.

6. Pauken, K. E. and Wherry, E. J. (2015). Overcoming T cell exhaustion in infection and cancer. Trends Immunol, 36, 265–276.
7. Patel, S. P. and Kurzrock, R. (2015). PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 14, 847–856.
8. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., and Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 366(26), 2443-54.
9. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., Pitot, H.C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T.M., Alaparthy, S., Grosso, J.F., Korman, A.J., Parker, S.M., Agrawal, S., Goldberg, S.M., Pardoll, D.M., Gupta, A., and Wigginton, J.M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 366(26), 2455-65.
10. Poirot, L., Philip, B., Schiffer-Mannioui, C., LeClerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., Lebuhotel, C., Eyquem, J., Cheung, G.W., Duclert, A., Gouble, A., Arnould, S., Peggs, K., Pule, M., Scharenberg, A.M., and Smith, J. (2015) Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Cancer Res, 75(18), 3853-64.
11. Keir, M. E., Butte, M. J., Freeman, G. J. and Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 26, 677–704.
12. Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. and Lim, W. A. (2015). Remote control of therapeutic T cells through a small moleculegated chimeric receptor. Science, 350, 4077.
13. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L., and Grupp, S.A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 371(16), 1507-17.
14. Kleffel, S., Posch, C., Barthel, S.R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C.P., Lee, N., Juneja, V.R., Zhan, Q., Lian, C.G., Thomi, R., Hoetzenecker, W., Cozzio, A., Dummer, R., Mihm, M.C., Flaherty, K.T., Frank, M.H., Murphy, G.F., Sharpe, A.H., Kupper, T.S., and Schatton, T. (2015). Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell, 162(6), 1242-56.
15. Zhao, Z., Condomines, M., vander-Stegen, S.J.C., Perna, F., Kloss, C.C., Gunset, G., Plotkin, J., and Sadelain, M. (2015). Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell, 28(4), 415-428.
16. Torikai, H., Reik, A., Liu, P.Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J.C., Kebriaei, P., Rabinovich, B., Lee, D.A., Champlin, R.E., Bonini, C., Naldini, L., Rebar, E.J., Gregory, P.D., Holmes, M.C., and Cooper, L.J. (2012). A foundation for universal T-cell based immunotherapy: T cells engineered to

express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood, 119(24), 5697-705.
17. Berdien, B., Mock, U., Atanackovic, D. and Fehse, B. (2014). TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Therapy, 21, 539–548.
18. Iqbal, F., Asif, M. S., Qureshi, A. G., Shah, J. A., Abdikaxarovich, S. A., Adil, M. N., and Hussain, A. (2023). RPA-Based colorimetric detection of SARS-Cov-2 (Covid-19) and its physiological effects. International Journal of Health Sciences, 6(S7). https://doi.org/10.53730/ijhs.v6nS7.13862
19. Iqbal, F., and Shabbir, M.I. (2021). Genetic analysis with pyrosequencing using loop pipetting and a light dependent resistor. Analytical Methods, 13, 5035-5047.
20. Naveed, A. M., Royaidar, J., Wadie, Y. R. R., GonzagaLeong-on, M. S., Iqbal, F., Hussain, A., Ali. Q., and Rasheed, A. (2022). Epidemiology and Resistance Pattern in Microbial Pneumonia: A Review: Epidemiology and Resistance Pattern in Microbial Pneumonia. Pakistan Journal of Health Sciences, 3 (05), 27-31.
21. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237–45.
22. James B. N., Nyla A. H., Harland S., Bruce C., Erik F., Christine J. H., Nicole D., Martin S., Ching-Hon P., Giuseppe B., Lewis B. S., Gritta E. J. (2007). Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood, 110 (4), 1112–1115.
23. Linda H., Lei W., Ernesto D., Michael W., Jinghui Z., Li D., Debbie P., Michelle C., Anna A., Shann C., Kelly M., Jared B., Jing M., Gang W., Samir N. P., Susan L. H., Letha A. P., Guangchun S., John E., Matthew P., Xiang C., Michael R., Kristy B., Bhavin V., Charles G. M. (2013). The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics, 45, 242-252.
24. Pui C. H., Carroll A. J., Raimondi S. C., Land V. J., Crist W. M., Shuster J. J., Williams D. L., Pullen D. J., Borowitz M. J., Behm F. G. (1990). Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood, 75 (5), 1170–1177.